Micropulsed Cyclofotocoagulation In Patients Affected By Early Or Moderate Stage Of Primary Glaucoma
Published 2025 - 43rd Congress of the ESCRS
Reference: PO658 | Type: Free paper | DOI: 10.82333/gy4v-mg27
Authors: Tadas Naujokaitis* 1 , Gerd U. Auffarth 1 , Louise Blöck 1 , Katharina Fabian 1 , Lucy Joanne Kessler 1 , Grzegorz Łabuz 1 , Ramin Khoramnia 2
1Department of Ophthalmology,University of Heidelberg,Heidelberg,Germany, 2Department of Ophthalmology,Carl Gustav Carus Dresden University Hospital,Dresden,Germany;Department of Ophthalmology,University of Heidelberg,Heidelberg,Germany
Purpose
To assess safety and efficacy of micropulse transscleral cyclophotocoagulation (MTS-CPC) in eyes affected by primary open angle glaucoma (POAG) or primary closed angle glaucoma (PCAG) in first stages of the disease at 1 year follow up.
Setting
Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy.
Methods
In this study were included 52 eyes of 36 patients (mean age 66.94 ± 12.5 years), affected by POAG at early or moderate stage according toHodapp’s classification, and 22 eyes of 18 patients (63.53 ± 15.15 years), affected by POAG at early or moderate stage according to Hodapp’s classification.Every patient was treated with MTS-CPC, they underwent a complete eye visit, including gonioscopy, intraocular pressure (IOP), visual acuity, record of glaucoma medications. All these measurements were repeated 1, 3, 6 and 12 months follow up together with eventual complications. Every 6 months, patients underwent mean standard automated perimetry (SAP) and mean deviation (MD) was recorded.
Results
Before treatments, mean IOP of POAG eyes was 22.41 ± 8.7 mmHg, 9 of them were assuming oral acetazolamide. Before treatments, mean IOP of PCAG eyes was 23.55 ± 10.58 mmHg, mean drugs used was 3.61 ± 0.7, 3 of them were assuming oral acetazolamide. After 1 month no patients were assuming oral acetazolamide both in POAG and in PCAG. In the POAG eyes, a significant (p<0.01) reduction of mean IOP: 15.07 ± 3.89 mmHg was observed and it was still significant (p<0.01) at 1 year follow up: mean IOP was 13.64 ± 2.06, with no complication recorded. In PCAG eyes, a significant (p<0.01) reduction of mean IOP: 15.2 ± 3.88 mmHg was observed and it was still significant at 1 year follow up: mean IOP was 12.89 ± 2.29 (p<0.01) with no complication recorded.
Conclusions
According to data observed in this study, MTS-CPC is able to provide an IOP reduction just after 1 month and the lowering effect is present after 12 months too with saving of drugs used to stabilize the IOP. Even if these data need to be confirmed in further studies with longer follow up and larger cohort, they suggest that MTS-CPC could represents an interesting option in treatment of glaucoma eyes in early and moderate stages too.